From here:
GW Pharmaceuticals, best known for Sativex, its cannabis-based treatment for the treatment of spasticity due to multiple sclerosis, says it may have come up with a similar compound that could represent a major advance in epilepsy.
The UK-based drugmaker noted that one of its partners, the University of Reading, has unveiled promising data from studies on cannabidivarin (CBDV), "a largely ignored natural compound found in cannabis that could lead to better treatments for epilepsy". The work was funded by, and performed, in collaboration with GW and Otsuka Pharmaceuticals; the latter two firms joined forces in July 2007 in a global cannabinoid research collaboration that currently runs to the end of June 2013.
Reading University’s Department of Pharmacy and School of Psychology have discovered in preclinical studies that CBDV has the potential to prevent more seizures, with few side effects such as uncontrollable shaking, caused by many existing anti-epileptics. It was also found to work when combined with the latter drugs, and unlike other cannabinoids, CBDV is not psychoactive and therefore does not cause users to feel high, GW notes. The findings are reported in the British Journal of Pharmacology.
Well, another magic treatment! The product is natural... If a modern pharma paradigm cannot help and even has no an worthwhile idea regarding epilepsy treatment – let's try anything – even cannabis! It will not harm that much!
No comments:
Post a Comment